GlassScriptPhysician profile
Dana Zanone
NPI 1578507968
$1,337.13
in general payments reported to CMS, 2019-2025
26 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $168 · 2023: $391 · 2024: $345 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $408.15 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $165.08 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $83.43 | 2022-2025 | Mounjaro, Jardiance, Lyumjev |
| Astrazeneca Pharmaceuticals LP | $77.21 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Xeris Pharmaceuticals, INC. | $47.76 | 2022-2023 | Gvoke Hypopen, Recorlev |
| Alkermes, INC. | $46.88 | 2023-2025 | Vivitrol, Vivitrol |
| Bayer Healthcare Pharmaceuticals INC. | $41.51 | 2024-2025 | |
| Ibsa Pharma INC. | $40.52 | 2022 | |
| Radius Health, INC. | $38.31 | 2025 | Tymlos |
| Glaxosmithkline, LLC. | $37.41 | 2024-2025 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $36.66 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $35.72 | 2023 | Verquvo, Belsomra, Steglatro |
| Dexcom, INC. | $35.56 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.43 | 2022 | |
| Amgen INC. | $27.24 | 2023 | Repatha, Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.38 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $22.95 | 2025 | Korlym |
| Renalytix Ai, INC. | $22.74 | 2022 | |
| Antares Pharma, INC. | $19.03 | 2025 | Xyosted |
| Horizon Therapeutics Plc | $17.92 | 2023 | Tepezza |
| Janssen Pharmaceuticals, INC | $14.97 | 2022 | |
| Nevro Corp. | $14.00 | 2023 | Senza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.99 | 2023 | Lifevest |
| Currax Pharmaceuticals LLC | $13.41 | 2024 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $12.95 | 2022 | |
| Pfizer INC. | $12.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Zanone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.